---
schema_version: "secwatch.filing_event.v1"
accession: "0000310764-26-000006"
form_type: "8-K"
ticker: "SYK"
cik: "0000310764"
company_name: "STRYKER CORP"
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:38:34.872519+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Stryker reports Q4 2025 sales $7.2B, +11% organic; 2026 outlook 8-9.5% organic growth

## Summary
- Q4 reported EPS $2.20 (+56% YoY); adjusted EPS $4.47 (+11.5%).
- Full year net sales $25.1B (+11.2% reported); organic growth 10.3%.
- MedSurg & Neurotechnology Q4 organic sales +12.6%; Orthopaedics +8.4% organic.
- Adjusted operating margin expanded 100 bps to 30.2% in Q4, 26.3% full year.
- 2026 guidance: organic sales growth 8.0%-9.5%; adjusted EPS $14.90-$15.10.

## SEC filing metadata
- accession: 0000310764-26-000006
- form_type: 8-K
- ticker: SYK
- cik: 0000310764
- company_name: STRYKER CORP
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310764/000031076426000006/0000310764-26-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310764/000031076426000006/syk-20260129.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000310764-26-000006
- JSON: https://secwatch.observer/filing/0000310764-26-000006.json
- Plain text: https://secwatch.observer/filing/0000310764-26-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.